# Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

> **NCT02579564** · PHASE3 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 134 (estimated)

## Conditions studied

- Malignant Hydrothorax
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Oncorine
- **DRUG:** Endostar
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02579564
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579564, "Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02579564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*